The standard treatment for patients with advanced-stage non-small-cell lung cancer with a performance status of 2 is unclear because of the heterogeneity of this population. Although a recent trial suggests that carboplatin plus pemetrexed improves survival as compared to single-agent pemetrexed, we should be cautious when defining new standards of treatment on the basis of single small trials.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Gridelli, C. et al. Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel. Ann. Oncol. 15, 419–426 (2004).
Gridelli, C. Treatment of patients with advanced non-small-cell lung cancer with performance status of 2: an unsolved issue. Clin. Lung Cancer 9, 324–325 (2008).
Azzoli, C. G. et al. American Society of Clinical Oncology clinical practice guidelines update on chemotherapy for stage IV non-small-cell lung cancer. J. Clin. Oncol. 27, 6251–6266 (2009).
Peters, S. et al. Metastatic non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 23 (Suppl. 7), vii56–vii64 (2012).
Zukin, M. et al. Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group performance status of 2. J. Clin. Oncol. http://dx.doi.org/10.1200/JCO.2012.48.1911.
Morabito, A. et al. Randomized phase III trial of gemcitabine and cisplatin vs gemcitabine alone in patients with advanced non-small cell lung cancer and a performance status of 2: the CAPPA-2 study. Lung Cancer 81, 77–83 (2013).
Lilenbaum, R. et al. Single-agent versus combination chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2: prognostic factors and treatment selection based on two large randomized clinical trials. J. Thorac. Oncol. 4, 869–874 (2008).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author has received speaker's honoraria and serves as an advisory board member for the following company: Eli Lilly.
Rights and permissions
About this article
Cite this article
Gridelli, C. Defining standard of care for performance status 2—don't rush. Nat Rev Clin Oncol 10, 490–492 (2013). https://doi.org/10.1038/nrclinonc.2013.134
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2013.134
